Revive Therapeutics Advances with Next-Generation Bucillamine Development

by rvvadmin | Jun 4, 2025 | 2025

TORONTO, June 04, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is pleased to announce the...

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

by rvvadmin | May 12, 2025 | 2025

TORONTO, May 12, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures,...

Revive Therapeutics Announces Proposed Shares for Debt Transaction

by rvvadmin | Apr 21, 2025 | 2025

TORONTO, April 21, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...

Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment

by rvvadmin | Apr 10, 2025 | 2025

TORONTO, April 10, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...

Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

by rvvadmin | Apr 1, 2025 | 2025

TORONTO, April 01, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...